{"id":34684,"date":"2025-06-25T11:07:33","date_gmt":"2025-06-25T05:37:33","guid":{"rendered":"https:\/\/edunovations.com\/currentaffairs\/?p=34684"},"modified":"2025-06-25T11:07:37","modified_gmt":"2025-06-25T05:37:37","slug":"fda-approved-hiv-prevention-shot","status":"publish","type":"post","link":"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/","title":{"rendered":"FDA Approved HIV Prevention Shot Yeztugo: Twice-Yearly Injection Revolutionizes PrEP in 2025"},"content":{"rendered":"\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#FDA_approved_HIV_prevention_shot_Yeztugo_lenacapavir_in_June_2025_as_the_first_twice-yearly_injection_for_HIV_PrEP_offering_nearly_100_efficacy_and_transforming_public_health_strategies_globally\" >FDA approved HIV prevention shot Yeztugo (lenacapavir) in June 2025 as the first twice-yearly injection for HIV PrEP, offering nearly 100% efficacy and transforming public health strategies globally.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#%F0%9F%A7%AC_US_FDA_Approves_Twice%E2%80%91Yearly_HIV_Prevention_Shot\" >\ud83e\uddec US FDA Approves Twice\u2011Yearly HIV Prevention Shot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#%F0%9F%92%A1_Clinical_Efficacy_Mechanism_Explained\" >\ud83d\udca1 Clinical Efficacy &amp; Mechanism Explained<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#%F0%9F%92%B0_Pricing_Coverage_Access_Barriers\" >\ud83d\udcb0 Pricing, Coverage &amp; Access Barriers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#%F0%9F%8C%8D_Implications_for_HIV_Prevention\" >\ud83c\udf0d Implications for HIV Prevention<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#%F0%9F%95%B0_Why_This_News_Matters\" >\ud83d\udd70 Why This News Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#%F0%9F%95%B0_Historical_Context\" >\ud83d\udd70 Historical Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#%F0%9F%93%8A_Key_Takeaways_from_FDA_Approval_of_Yeztugo\" >\ud83d\udcca Key Takeaways from FDA Approval of Yeztugo<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#%E2%9C%85_Frequently_Asked_Questions_FAQs\" >\u2705 Frequently Asked Questions (FAQs)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/edunovations.com\/currentaffairs\/international\/fda-approved-hiv-prevention-shot\/#Some_Important_Current_Affairs_Links\" >Some Important Current Affairs Links<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_approved_HIV_prevention_shot_Yeztugo_lenacapavir_in_June_2025_as_the_first_twice-yearly_injection_for_HIV_PrEP_offering_nearly_100_efficacy_and_transforming_public_health_strategies_globally\"><\/span><strong>FDA approved HIV prevention shot Yeztugo<\/strong> (lenacapavir) in June 2025 as the first twice-yearly injection for HIV PrEP, offering nearly 100% efficacy and transforming public health strategies globally.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%F0%9F%A7%AC_US_FDA_Approves_Twice%E2%80%91Yearly_HIV_Prevention_Shot\"><\/span>\ud83e\uddec US FDA Approves Twice\u2011Yearly HIV Prevention Shot<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>June 18, 2025<\/strong>, the U.S. Food and Drug Administration (FDA) granted approval to <strong>lenacapavir<\/strong>, branded as <strong>Yeztugo<\/strong>, marking a pivotal shift in pre\u2011exposure prophylaxis (PrEP). Developed by Gilead Sciences, this long\u2011acting injectable works by inhibiting the HIV capsid protein. Remarkably, it demonstrated nearly <strong>100% efficacy<\/strong> in clinical trials among high-risk populations\u201496% in cisgender women, and 100% in men who have sex with men (MSM) and gender-diverse individuals <\/p>\n\n\n\n<p>This subcutaneous injection, administered every <strong>six months<\/strong>, contrasts sharply with daily oral PrEP pills like Truvada and Descovy, offering greater convenience and potentially higher adherence The FDA\u2019s approval also follows lenacapavir\u2019s earlier authorization in 2022 for treating drug-resistant HIV under the name Sunlenca <\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%F0%9F%92%A1_Clinical_Efficacy_Mechanism_Explained\"><\/span>\ud83d\udca1 Clinical Efficacy &amp; Mechanism Explained<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Lenacapavir targets the HIV capsid\u2014the protein shell protecting the virus\u2014which disrupts its replication. This new regimen initiates with oral loading doses followed by bian\u00adnual injections  Clinical data highlights:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cisgender women<\/strong> in Africa: 0% infections in the injection group vs. 2% with daily pills <\/li>\n\n\n\n<li><strong>MSM and gender-diverse individuals<\/strong> globally: trial showed nearly <strong>100% effectiveness<\/strong> <\/li>\n<\/ul>\n\n\n\n<p>These results rival an effective vaccine, but lenacapavir isn&#8217;t a vaccine\u2014it prevents infection pharmacologically <\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%F0%9F%92%B0_Pricing_Coverage_Access_Barriers\"><\/span>\ud83d\udcb0 Pricing, Coverage &amp; Access Barriers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Yeztugo is priced at <strong>$28,218 per year<\/strong> (two injections) in the U.S., or about <strong>$14,109 per dose<\/strong> While Gilead anticipates insurance will cover it, concerns remain regarding out-of-pocket costs and coverage gaps amid evolving Medicaid policies<\/p>\n\n\n\n<p>Internationally, Gilead has entered royalty-free licensing with six generic manufacturers to supply <strong>120 low- and middle-income countries<\/strong>\u2013\u2013enough for 2 million recipients at no profit until generics are available Still, access is uneven\u2014middle-income countries may be left out .<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%F0%9F%8C%8D_Implications_for_HIV_Prevention\"><\/span>\ud83c\udf0d Implications for HIV Prevention<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Public health leaders view this approval as a potential game\u2011changer:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Improved adherence<\/strong>: By eliminating daily pill fatigue and stigma tied to pill-taking <\/li>\n\n\n\n<li><strong>Vaccine research impact<\/strong>: Its effectiveness raises ethical challenges for HIV vaccine trial designs <\/li>\n\n\n\n<li><strong>Policy &amp; infrastructure needs<\/strong>: Success hinges on robust funding, healthcare access, community outreach, and logistical support .<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\" id=\"FDA-approved-HIV-prevention-shot\"><img decoding=\"async\" src=\"https:\/\/encrypted-tbn0.gstatic.com\/images?q=tbn:ANd9GcTCVBLjgzxePlholJLM6DqeIth40FfZixcfwQ&amp;s\" alt=\"FDA approved HIV prevention shot\" title=\"FDA approved HIV prevention shot\"\/><figcaption class=\"wp-element-caption\">FDA approved HIV prevention shot<\/figcaption><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%F0%9F%95%B0_Why_This_News_Matters\"><\/span>\ud83d\udd70 Why This News Matters<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Understanding lenacapavir\u2019s approval is crucial for aspirants in government exams\u2014especially in General Studies, Health &amp; Social Justice, and Public Policy:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Healthcare Strategy<\/strong>: Reflects modern strategies in disease prevention and pharmaceutical innovations.<\/li>\n\n\n\n<li><strong>Global Health &amp; Policy<\/strong>: Illuminates complexities in international public health financing, drug distribution, and equity.<\/li>\n\n\n\n<li><strong>Science &amp; Technology Scope<\/strong>: Highlights progress in pharmacology, capsid inhibitors, and long-acting therapeutics.<\/li>\n\n\n\n<li><strong>Regulatory &amp; Ethical Dimensions<\/strong>: Raises discussion points about FDA processes, trial ethics, and access disparities.<\/li>\n<\/ol>\n\n\n\n<p>These insights can fuel precise answer-writing in exams related to healthcare policies, international cooperation, and scientific ethics.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%F0%9F%95%B0_Historical_Context\"><\/span>\ud83d\udd70 Historical Context<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capsid inhibitor innovation<\/strong>: Lenacapavir belongs to a novel class targeting the viral capsid\u2014first approved for treatment in December 2022 as Sunlenca <\/li>\n\n\n\n<li><strong>Progress in long\u2011acting PrEP<\/strong>: Prior to Yeztugo, FDA approved injectable cabotegravir (Apretude) in 2021 for bi-monthly use <\/li>\n\n\n\n<li><strong>HIV prevention evolution<\/strong>: From daily pills (Truvada circa 2012) to modern injectables, reflecting advances in adherence solutions amid global HIV policy initiatives like PEPFAR and UNAIDS.<\/li>\n\n\n\n<li><strong>Funding fluctuations<\/strong>: As U.S. support wanes, infrastructure support and equitable access remain vital to realising this breakthrough <\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%F0%9F%93%8A_Key_Takeaways_from_FDA_Approval_of_Yeztugo\"><\/span>\ud83d\udcca Key Takeaways from FDA Approval of Yeztugo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>S.No<\/th><th>Key Takeaway<\/th><\/tr><\/thead><tbody><tr><td>1<\/td><td><strong>First twice-yearly PrEP injection<\/strong> approved June 18, 2025 by FDA<\/td><\/tr><tr><td>2<\/td><td><strong>Nearly 100% efficacy<\/strong> in clinical trials for high-risk groups<\/td><\/tr><tr><td>3<\/td><td><strong>$28,218\/year<\/strong> U.S. list price; insurance and assistance expected<\/td><\/tr><tr><td>4<\/td><td><strong>Royalty-free licensing<\/strong> for generics in 120 low\/middle-income nations<\/td><\/tr><tr><td>5<\/td><td><strong>Vaccine trials face ethical challenges<\/strong> due to lenacapavir\u2019s effectiveness<\/td><\/tr><\/tbody><\/table><figcaption class=\"wp-element-caption\">FDA approved HIV prevention shot<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%E2%9C%85_Frequently_Asked_Questions_FAQs\"><\/span>\u2705 <strong>Frequently Asked Questions (FAQs)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Q1. What is Yeztugo and how is it different from other HIV PrEP methods?<\/strong><br><strong>Ans:<\/strong> Yeztugo is a long-acting injectable PrEP drug, scientifically known as lenacapavir. Unlike daily oral PrEP pills like Truvada and Descovy, Yeztugo is administered just twice a year, making adherence easier and stigma around daily medication less of a barrier.<\/p>\n\n\n\n<p><strong>Q2. Who developed Yeztugo and what does it target?<\/strong><br><strong>Ans:<\/strong> Yeztugo has been developed by Gilead Sciences. It is a capsid inhibitor, which means it targets the protein shell of the HIV virus, disrupting its replication.<\/p>\n\n\n\n<p><strong>Q3. When was Yeztugo approved by the FDA for HIV prevention?<\/strong><br><strong>Ans:<\/strong> The US FDA approved Yeztugo for HIV prevention on <strong>June 18, 2025<\/strong>.<\/p>\n\n\n\n<p><strong>Q4. How effective is Yeztugo in clinical trials?<\/strong><br><strong>Ans:<\/strong> In trials, Yeztugo showed <strong>96% efficacy<\/strong> in cisgender women and <strong>100% efficacy<\/strong> among men who have sex with men (MSM) and gender-diverse individuals.<\/p>\n\n\n\n<p><strong>Q5. Will Yeztugo be accessible to developing countries?<\/strong><br><strong>Ans:<\/strong> Yes, Gilead has signed royalty-free agreements with generic manufacturers to provide access to 120 low- and middle-income countries, especially in Africa, until generics are fully available.<\/p>\n\n\n\n<p><strong>Q6. What ethical issues does this drug raise?<\/strong><br><strong>Ans:<\/strong> Due to its high efficacy, it could potentially complicate the design and justification of future placebo-controlled HIV vaccine trials.<\/p>\n\n\n\n<p><strong>Q7. What is the price of Yeztugo in the US?<\/strong><br><strong>Ans:<\/strong> It costs approximately <strong>$28,218 per year<\/strong> (or <strong>$14,109 per injection<\/strong>) in the United States, although insurance and government programs may help offset the cost.<\/p>\n\n\n\n<p><br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Some_Important_Current_Affairs_Links\"><\/span>Some Important Current Affairs Links<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/national\/\" target=\"_blank\" rel=\"noreferrer noopener\">State Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--2\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/sports\/\" target=\"_blank\" rel=\"noreferrer noopener\">Sports Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--3\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/international\/\" target=\"_blank\" rel=\"noreferrer noopener\">International Current Affairs<\/a><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/banking\/\" target=\"_blank\" rel=\"noreferrer noopener\">Banking Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/railway\/\" target=\"_blank\" rel=\"noreferrer noopener\">Railways Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/defence\/\" target=\"_blank\" rel=\"noreferrer noopener\">Defence Current Affairs<\/a><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--4\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs?newsmaticargs=custom&amp;posts=today\" target=\"_blank\" rel=\"noreferrer noopener\">Daily Current Affairs<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--5\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairsinhindi\/\" target=\"_blank\" rel=\"noreferrer noopener\">Current Affairs In Hindi<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--6\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/edunovations.com\/currentaffairs\/category\/news-and-notifications\/\" target=\"_blank\" rel=\"noreferrer noopener\">News and Notifications<\/a><\/div>\n<\/div>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.edunovations.quiz\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"900\" height=\"150\" src=\"https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/03\/Banner-current-affairs-2-1.jpg\" alt=\"Download this App for Daily Current Affairs MCQ&#039;s\" class=\"wp-image-247\" title=\"\" srcset=\"https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/03\/Banner-current-affairs-2-1.jpg 900w, https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/03\/Banner-current-affairs-2-1-300x50.jpg 300w, https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/03\/Banner-current-affairs-2-1-768x128.jpg 768w\" sizes=\"(max-width: 900px) 100vw, 900px\" \/><\/a><figcaption class=\"wp-element-caption\">Download this App for Daily Current Affairs MCQ&#8217;s<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\" id=\"News-Website-Development-Company\"><a href=\"https:\/\/www.martindiainfotech.com\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"900\" height=\"150\" src=\"https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/04\/News-Website-Development-Company-Banner.png\" alt=\"News Website Development Company\" class=\"wp-image-438\" title=\"News Website Development Company\" srcset=\"https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/04\/News-Website-Development-Company-Banner.png 900w, https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/04\/News-Website-Development-Company-Banner-300x50.png 300w, https:\/\/edunovations.com\/currentaffairs\/wp-content\/uploads\/2023\/04\/News-Website-Development-Company-Banner-768x128.png 768w\" sizes=\"(max-width: 900px) 100vw, 900px\" \/><\/a><figcaption class=\"wp-element-caption\">News Website Development Company<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>FDA approved HIV prevention shot Yeztugo (lenacapavir) in June 2025 as the first twice-yearly injection for HIV PrEP, offering nearly 100% efficacy and transforming public health strategies globally. . \ud83e\uddec US FDA Approves Twice\u2011Yearly HIV Prevention Shot On June 18, 2025, the U.S. Food and Drug Administration (FDA) granted approval to lenacapavir, branded as Yeztugo,&#8230;<\/p>\n","protected":false},"author":6,"featured_media":34710,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,153],"tags":[23844,23845,23840,23843,23847,23842,440,23846,23839,23841],"class_list":["post-34684","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-international","category-miscellaneous","tag-gilead-sciences","tag-hiv-drug-approval-2025","tag-hiv-prevention","tag-lenacapavir","tag-pharma-news","tag-prep","tag-public-health","tag-twice-yearly-injection","tag-us-fda","tag-yeztugo"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/posts\/34684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/comments?post=34684"}],"version-history":[{"count":2,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/posts\/34684\/revisions"}],"predecessor-version":[{"id":34711,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/posts\/34684\/revisions\/34711"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/media\/34710"}],"wp:attachment":[{"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/media?parent=34684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/categories?post=34684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/edunovations.com\/currentaffairs\/wp-json\/wp\/v2\/tags?post=34684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}